重组人Ⅱ型肿瘤坏死因子受体—抗体融合蛋白治疗类风湿关节炎的成本—效用分析(5)
[ 9 ] KIELHORN A，PORTER D，DIAMANTOPOULOS A，et al. UK cost-utility analysis of rituximab in patients with rheumatoid arthritis that failed to respond adequately to a biologic disease-modifying antirheumatic drug[J]. Curr Med Res Opin，2008，24(9)：2639-2650.
[10] BOGGS R，SENGUPTA N，ASHRAF T. Estimating health utility from a physical function assessment in rheumatoid arthritis (RA) patients treated with adalimumab (D2E7)[J]. Value Health，2002，5(6)：452-453.
[11] KOBELT G，EBERHARDT K，JONSSON L，et al. Economic consequences of the progression of rheumatoid arthritis in Sweden[J]. Arthritis Rheum，1999，42(2)：347- 356.
[12] TAN Q，GUO Q，FANG C，et al. Characterization and comparison of commercially available TNF receptor 2-Fc fusion protein products[J]. Mabs，2012，4(6)：761-774.
[13] ADAMS R，WALSH G，VEALE D，et al. Understanding the relationship between the EQ-5D，SF-6D，HAQ and disease activity in inflammatory arthritis[J]. Pharmacoeconomics，2010，28(6)：477-487.
(收稿日期：2017-05-02 修回日期：2017-08-01)
(編辑：邹丽娟), http://www.100md.com(张崖冰 胡善联 何江江)
[10] BOGGS R，SENGUPTA N，ASHRAF T. Estimating health utility from a physical function assessment in rheumatoid arthritis (RA) patients treated with adalimumab (D2E7)[J]. Value Health，2002，5(6)：452-453.
[11] KOBELT G，EBERHARDT K，JONSSON L，et al. Economic consequences of the progression of rheumatoid arthritis in Sweden[J]. Arthritis Rheum，1999，42(2)：347- 356.
[12] TAN Q，GUO Q，FANG C，et al. Characterization and comparison of commercially available TNF receptor 2-Fc fusion protein products[J]. Mabs，2012，4(6)：761-774.
[13] ADAMS R，WALSH G，VEALE D，et al. Understanding the relationship between the EQ-5D，SF-6D，HAQ and disease activity in inflammatory arthritis[J]. Pharmacoeconomics，2010，28(6)：477-487.
(收稿日期：2017-05-02 修回日期：2017-08-01)
(編辑：邹丽娟), http://www.100md.com(张崖冰 胡善联 何江江)